Abstract:Background: Patients with rectal cancer who achieve pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) may have a better prognosis and may be eligible for non-operative management. The aim of this research was to identify variables for predicting pCR in rectal cancer patients after nCRT and to define clinical risk factors for poor outcome after pCR to nCRT and radical resection in rectal cancer patients. Methods: A retrospective review was performed using the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2013. Non-metastatic rectal cancer patients who received radical resection after neoadjuvant chemoradiotherapy were included in this study. Multivariate analysis of the association between clinicopathological characteristics and pCR was performed, and a logistic regression model was used to identify independent predictors for pCR. A nomogram based on the multivariate logistics regression was built with decision curve analyses to evaluate the clinical usefulness. Results: A total of 6,555 patients were included in this study. The proportion of patients with pCR was 20.5% (n = 1,342). The nomogram based on multivariate logistic regression analysis showed that clinical T4 and N2 stages were the most significant independent clinical predictors for not achieving pCR, followed by mucinous adenocarcinoma and positive pre-treatment serum CEA results. The 3-year overall survival rate was 92.4% for those with pCR and 88.2% for those without pCR. Among all the pCR patients, mucinous adenocarcinoma patients had the worst survival, with a 3-year overall survival rate of 67.5%, whereas patients with common adenocarcinoma had an overall survival rate of 93.8% (P < 0.001). Univariate and multivariate analyses showed that histology and clinical N2 stage were independent risk factors. Conclusion: Mucinous adenocarcinoma, positive pre-treatment serum CEA results, and clinical T4 and N2 stages may impart difficulty for patients to achieve pCR. Mucinous adenocarcinoma and clinical N2 stage might be indicative of a prognostically unfavorable biological tumor profile with a greater propensity for local or distant recurrence and decreased survival.

Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients

P53 Status As a Predictive Biomarker for Patients Receiving Neoadjuvant Radiation-Based Treatment: A Meta-Analysis in Rectal Cancer

[Detection and Clinical Significance of Apoptosis Related Protein in Local Advanced Rectal Cancer Patients with Preoperative Neoadjuvant Therapy].

[Effect of Preoperative Radiotherapy As an Adjunctive Approach on Proliferation and Apoptosis of Cancer Cells in Rectal Cancer].

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer

Comparative Study on Apoptosis,proliferation and Expression of Regulating Genes in Rectal Carcinoma Prior to and after Pre-Operative Radiotherapy

p21 as a Predictor and Prognostic Indicator of Clinical Outcome in Rectal Cancer Patients

[Expression and Clinical Significance of P53 Protein and P21(waf1) in Non-Small-cell Lung Carcinoma].

[Efficacy Assessment of Preoperative Radiochemotherapy and Analysis of Associated Factors in Rectal Cancer].

Prognostic Value of Immunohistochemical Markers for Locally Advanced Rectal Cancer

The Relationship Between Pim-3 Expression and Chemoradiotherapy Resistance in Locally Advanced Rectal Cancer Patients.

P53 Gene Mutation Predicts Lymph Node Disease Following Neoadjuvant Chemoradiation Therapy in Rectal Cancer Patients

Clinical significance of the post/preoperative anti-p53 antibody ratio in predicting the prognosis of patients with colorectal cancer after curative surgery and its usefulness in combination with carcinoembryonic antigen

p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy

The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells

Immunohistochemistry of p53 surrogates TP53 mutation as an accurate predictor for early-relapse of surgically resected stage I-III lung adenocarcinoma

Effects of P53 Expression on Prognosis and Adjuvant Chemotherapy and Radiotherapy in NSCLC

Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.

Expression of Ki67 and p53 and their Relationship with the Survival Time of High-Dose Hypofractionated Radiotherapy in Pancreatic Cancer

Clinical Significance of P53 Expression in Colorectal Cancer Patients